Robert W. Baird Raises Medpace (NASDAQ:MEDP) Price Target to $362.00

Medpace (NASDAQ:MEDP - Free Report) had its price target hoisted by Robert W. Baird from $354.00 to $362.00 in a research report report published on Monday morning,Benzinga reports. Robert W. Baird currently has a neutral rating on the stock.

MEDP has been the subject of a number of other reports. William Blair reiterated an "outperform" rating on shares of Medpace in a report on Tuesday, October 22nd. Baird R W cut shares of Medpace from a "strong-buy" rating to a "hold" rating in a research note on Wednesday, October 23rd. Truist Financial reduced their price target on shares of Medpace from $415.00 to $397.00 and set a "hold" rating for the company in a report on Monday, October 14th. TD Cowen dropped their price objective on shares of Medpace from $413.00 to $372.00 and set a "buy" rating on the stock in a report on Wednesday, October 23rd. Finally, Redburn Atlantic assumed coverage on shares of Medpace in a research note on Monday, October 14th. They issued a "buy" rating and a $404.00 target price for the company. Seven analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. According to MarketBeat, the company presently has an average rating of "Hold" and a consensus price target of $381.44.

Medpace Trading Up 1.8 %

Medpace stock traded up $6.30 during trading hours on Monday, reaching $350.37. 184,137 shares of the company were exchanged, compared to its average volume of 216,271. Medpace has a 12 month low of $286.76 and a 12 month high of $459.77. The firm has a market cap of $10.89 billion, a price-to-earnings ratio of 30.68, a PEG ratio of 1.77 and a beta of 1.36. The stock has a 50-day moving average of $340.33 and a 200 day moving average of $354.73.

Hedge Funds Weigh In On Medpace

Hedge funds and other institutional investors have recently modified their holdings of the stock. Iron Triangle Partners LP acquired a new position in Medpace during the third quarter worth $64,371,000. Clearbridge Investments LLC grew its holdings in shares of Medpace by 55.1% in the 2nd quarter. Clearbridge Investments LLC now owns 403,892 shares of the company's stock worth $166,343,000 after purchasing an additional 143,481 shares during the last quarter. Wellington Management Group LLP increased its position in shares of Medpace by 36.0% during the 3rd quarter. Wellington Management Group LLP now owns 415,255 shares of the company's stock worth $138,612,000 after purchasing an additional 109,886 shares in the last quarter. DF Dent & Co. Inc. lifted its holdings in Medpace by 189.9% during the 3rd quarter. DF Dent & Co. Inc. now owns 161,298 shares of the company's stock valued at $53,841,000 after purchasing an additional 105,659 shares during the last quarter. Finally, Argent Capital Management LLC lifted its holdings in Medpace by 431.5% during the 3rd quarter. Argent Capital Management LLC now owns 91,732 shares of the company's stock valued at $30,620,000 after purchasing an additional 74,473 shares during the last quarter. Institutional investors own 77.98% of the company's stock.

Medpace Company Profile

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.